Cell and Gene Outsourcing

  1. Turnkey Dismantling, Modification, And Relocation Of A Multi-Glove Isolator System 1/30/2026

    Strategic equipment relocation and retrofitting can reduce capital costs by fifty percent and save months in lead time. Learn how to modernize legacy systems while maintaining full GMP compliance.

  2. Construct Viability: A Hidden Challenge In Viral Vector Manufacturing 1/30/2026

    Rapid, low‑cost checks can catch construct issues that limit vector manufacturing, enabling early fixes to improve titers, avoid delays, and accelerate gene therapy programs.

  3. Viral Clearance Strategies For Monoclonal Antibodies And Proteins 1/30/2026

    Guidance on designing viral clearance studies using regulatory-aligned, risk‑based strategies, optimized assays, and real case examples for safe, efficient biologics development.

  4. A Year Of Separation: Which Advanced Modalities Are Built For Commercial Scale In 2026? 1/30/2026

    In 2026, advanced therapies diverge: winners pair proven biology with scalable manufacturing, delivery, and workflow fit, while others advance more slowly under operational and economic limits.

  5. How Can Data Translation Challenges In CRO Partnerships Be Overcome? 1/29/2026

    Biopharma–CRO partnerships often struggle with fragmented communication. Gain insight into how streamlined, automated workflows improve transparency, data quality, and operational speed.

  6. Scaling Cell And Gene Therapies: Crossing The Inflection Point 1/29/2026

    Progress in cell and gene therapy hinges on aligning therapeutic design with scalable, efficient manufacturing to improve accessibility, reliability, and real‑world feasibility across advanced modalities.

  7. Building A Unique Portfolio Of Therapeutic Base Editors 1/29/2026

    Stepwise engineering produces ABEs with tunable potency, precision, PAM range, and context specificity, enabling robust and targeted genome editing across diverse therapeutic sites.

  8. Boosting Base Editors For Genomic Medicine 1/29/2026

    Advanced CRISPR and base‑editing technologies are engineered to enhance potency, specificity, PAM flexibility, and safety, enabling more precise and efficient development of genetic medicines.

  9. Commercially Proven Sterile Fill/Finish With Capacity And Global Backing 1/27/2026

    Find comprehensive solution with new sterile fill/finish investments supporting complex molecules through robust tech transfer, commercialization expertise, and integrated cGMP manufacturing solutions.

  10. PCI Pharma Services Capabilities Update January 2026: Fill/Finish 1/27/2026

    Patricia Krainski highlights PCI’s global sterile fill‑finish and lyophilization strengths, showcasing investments that expand capacity, technologies, and integrated solutions for complex biologics, formulations, and lyophilized products.